GlassScriptPhysician profile
Dilipkumar C Patel
NPI 1780619460
$2,806.80
in general payments reported to CMS, 2019-2025
10 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2021: $619 · 2022: $232 · 2023: $462 · 2024: $519 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $782.42 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $539.96 | 2019-2023 | Lybalvi |
| Tris Pharma INC | $365.73 | 2021-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $360.36 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $179.53 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $158.04 | 2022-2025 | Uzedy |
| Axsome Therapeutics, INC. | $118.54 | 2024 | Auvelity |
| Noven Pharmaceuticals, INC. | $114.23 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $98.34 | 2023 | Quviviq |
| Corium, LLC | $89.65 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilipkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.